- Home
- OGN vs BCRX Comparison
OGN vs BCRX Comparison
Compare OGN & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OGN | BCRX |
|---|---|---|
| Founded | 1923 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | OGN | BCRX |
|---|---|---|
| Price | $6.41 | $8.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $11.75 | ★ $20.82 |
| AVG Volume (30 Days) | 3.9M | ★ 4.2M |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | 0.72 | ★ 1.21 |
| Revenue | ★ $6,216,000,000.00 | $25,186,000.00 |
| Revenue This Year | $0.42 | N/A |
| Revenue Next Year | $1.67 | $12.55 |
| P/E Ratio | $8.98 | ★ $7.23 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.18 | $6.00 |
| 52 Week High | $15.88 | $11.31 |
Technical Indicators
Market Signals| Indicator | OGN | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.55 | 72.83 |
| Support Level | $6.34 | $7.95 |
| Resistance Level | $7.87 | $9.18 |
| Average True Range (ATR) | 0.30 | 0.32 |
| MACD | -0.09 | 0.09 |
| Stochastic Oscillator | 7.89 | 91.38 |
Price Performance
Historical ComparisonAbout OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.